Early detection, precision medicine, and wearables have quickly taken center stage in clinical trials—reshaping the way we approach research. With the explosion of data, an AI strategy is not just beneficial, it is imperative to meet the growing needs of clinical trial sponsors and patients alike.
Before an AI strategy can come into play, healthcare and technology leaders must define a data and data-sharing strategy to create infrastructure to scale. With the help of non-invasive data collection, advanced technologies, and AI, we can accelerate clinical research, solving the unique challenges posed by both rare diseases and common diseases.
For rare disease trials, AI holds immense promise by enabling the analysis of complex datasets, identifying patterns and correlations that may lead to breakthroughs. AI can help accelerate the creation of targeted therapies tailored to individuals by driving a deeper understanding of overlooked conditions.
At YPrime’s annual Innovation Network Gathering, we sat down with Rohit Nambisan, Founder and CEO of Lokavant, to discuss what clinical trial sponsors, investigators, sites, and research coordinators should do to build an AI strategy. With the overarching goal to eradicate disease—especially rare ones—Nambisan shares simple steps to harness the power of AI. Take a listen here:
Innovation and quality are at the core of everything we do as an industry to improve clinical trials. That’s why every year, we host the Innovation Network Gathering—a forum for brilliant minds from various backgrounds to come together to engage in thought-provoking discourse that sparks new opportunities for growth and change.
Unlock the Potential of AI in Clinical Research
Explore additional resources below.
